cilostazol and Ischemia studies

Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.

Research Excerpts

Excerpt	Relevance	Reference
"To clarify the potential protective role of cilostazol on rat myocardial cells with ischemia-reperfusion injury (IRI) models."	8.12	Cardioprotective Effect of Cilostazol on Ischemia-Reperfusion Injury Model. ( Baytaroglu, C; Sahin, M; Sevgili, E, 2022)
" Cilostazol (CLZ) has pleiotropic effects including neuroprotection in several ravaging central disorders; nonetheless, its potential role in transient central ischemic-induced allodynia and hyperalgesia has not been asserted before."	8.12	Cilostazol Alleviates NLRP3 Inflammasome-Induced Allodynia/Hyperalgesia in Murine Cerebral Cortex Following Transient Ischemia: Focus on TRPA1/Glutamate and Akt/Dopamine/BDNF/Nrf2 Trajectories. ( Abdallah, DM; Mohammed, RA; Nassar, NN; Safar, MM; Zaki, OS, 2022)
"Cilostazol and L-carnitine have been used as a first-line drug and supplement, respectively, in patients with peripheral arterial disease with intermittent claudication."	7.81	Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats. ( Orito, K; Sahara, H; Shiga, T, 2015)
"The model of IR caused severe muscle injury in the rat hind limb and ischemic preconditioning has a protective effect, reducing myocyte necrosis, however, treatment with cilostazol and also the association between cilostazol and preconditioning has no protective effect on the skeletal muscle subjected to ischemia and reperfusion injury."	7.80	Effects of ischemic preconditioning and cilostazol on muscle ischemia-reperfusion injury in rats. ( Frias Neto, CA; Koike, MK; Montero, EF; Saad, KR; Saad, PF, 2014)
"We tested the hypothesis that clopidogrel and cilostazol combination therapy could effectively attenuate systemic inflammatory reaction, facilitate proliferation of circulating endothelial progenitor cell (EPC), and improve the clinical outcomes of critical limb ischemia (CLI) in patients unsuitable for surgical revascularization or percutaneous transluminal angioplasty (PTA)."	7.80	Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy. ( Chai, HT; Chang, HW; Chen, CH; Chen, YC; Chen, YL; Chua, S; Chung, SY; Ko, SF; Leu, S; Lin, PY; Sheu, JJ; Sung, PH; Tsai, TH; Yip, HK, 2014)
"Cilostazol is effective for the treatment of peripheral ischemia."	7.79	Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPARγ. ( Angelini, F; Arena, V; Biscetti, F; Ferraccioli, G; Flex, A; Ghirlanda, G; Pecorini, G; Stigliano, E, 2013)
"We studied ischemia-induced neovascularization in the ischemic hindlimb of cilostazol-treated and untreated control mice."	7.79	Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. ( Angelini, F; Arena, V; Biscetti, F; Flex, A; Ghirlanda, G; Locatelli, F; Pecorini, G; Rutella, S; Stigliano, E; Straface, G, 2013)
"To investigate the effect of cilostazol, in kidney and skeletal muscle of rats submitted to acute ischemia and reperfusion."	7.78	Effects of cilostazol in kidney and skeletal striated muscle of Wistar rats submitted to acute ischemia and reperfusion of hind limbs. ( Capelozzi, VL; Francisco Neto, A; Moreira Neto, AA; Parra-Cuentas, ER; Rodrigues, OR; Schmidt Júnior, AF; Souza Júnior, SS, 2012)
"Acetylcholine-and A23187-induced relaxation was reduced in the Ischemia/Reperfusion 120/90 group, and treatment with cilostazol partially prevented this ischemia/reperfusion-induced endothelium impairment."	7.78	The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway. ( Capellini, VK; Celotto, AC; Evora, PR; Joviliano, EE; Piccinato, CE; Santos, MR, 2012)
"Combined cilostazol-clopidogrel therapy is superior to either agent alone in improving ischemia in rodent CLI."	7.78	Combination of cilostazol and clopidogrel attenuates rat critical limb ischemia. ( Chang, HW; Chen, YL; Chua, S; Leu, S; Lin, KC; Sheu, JJ; Sun, CK; Tsai, CY; Tsai, TH; Yang, JL; Yen, CH; Yip, HK, 2012)
" This study investigated whether cilostazol could improve the vasodilatory response of the brachial artery to ischemia, an indicator of endothelial function, in ten male smokers."	7.72	Effect of cilostazol on impaired vasodilatory response of the brachial artery to ischemia in smokers. ( Ebata, K; Kanehara, H; Miyamori, I; Oida, K; Suzuki, J, 2003)
"Cilostazol is a new phosphodiesterase inhibitor that suppresses platelet aggregation and also acts as a direct arterial vasodilator."	6.69	Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. ( Cutler, BS; Dawson, DL; Meissner, MH; Strandness, DE, 1998)
"Cilostazol is a drug of choice for the treatment of intermittent claudication that also affects innate and adaptive immune cells."	5.56	Cilostazol Mediates Immune Responses and Affects Angiogenesis During the Acute Phase of Hind Limb Ischemia in a Mouse Model. ( Bouziotis, P; Kadoglou, NPE; Kakisis, I; Katsimpoulas, M; Kostomitsopoulos, NG; Kostopoulos, IV; Lazaris, A; Paronis, E; Poulaki, E; Prignon, A; Provost, C; Spyropoulos, C; Stasinopoulou, M; Tsitsilonis, O, 2020)
"Outcome measures were binary restenosis by angiogram, reocclusion, target lesion revascularization (TLR), limb salvage rate and complete wound healing at 3 months."	5.38	Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia. ( Hirano, K; Iida, O; Kawasaki, D; Soga, Y; Suzuki, K; Yamaoka, T, 2012)
"Cilostazol is a phosphodiesterase III inhibitor with a firm evidence base for use in intermittent claudication."	5.35	Cilostazol may improve outcome in critical limb ischemia. ( Davies, AH; Franklin, IJ; Shalhoub, J, 2009)
"Cilostazol (Pletal) was added to the medical regimen and at the 8-week follow-up the fourth and fifth fingers were warm with repeat plethysmography displaying normal perfusion."	5.31	Three cases of digital ischemia successfully treated with cilostazol. ( Dean, SM; Satiani, B, 2001)
" For patients with disabling intermittent claudication who do not respond to conservative measures and who are not candidates for surgical or catheter-based intervention, we suggest cilostazol (Grade 2A)."	4.82	Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. ( Clagett, GP; Jackson, MR; Lip, GY; Sobel, M; Tangelder, M; Verhaeghe, R, 2004)
" Cilostazol (CLZ) has pleiotropic effects including neuroprotection in several ravaging central disorders; nonetheless, its potential role in transient central ischemic-induced allodynia and hyperalgesia has not been asserted before."	4.12	Cilostazol Alleviates NLRP3 Inflammasome-Induced Allodynia/Hyperalgesia in Murine Cerebral Cortex Following Transient Ischemia: Focus on TRPA1/Glutamate and Akt/Dopamine/BDNF/Nrf2 Trajectories. ( Abdallah, DM; Mohammed, RA; Nassar, NN; Safar, MM; Zaki, OS, 2022)
"To clarify the potential protective role of cilostazol on rat myocardial cells with ischemia-reperfusion injury (IRI) models."	4.12	Cardioprotective Effect of Cilostazol on Ischemia-Reperfusion Injury Model. ( Baytaroglu, C; Sahin, M; Sevgili, E, 2022)
"The study was aimed at assessing efficacy and safety of treatment with Aducil® (cilostazol) compared with Trental® 400 in patients with moderate-to-severe intermittent claudication due to peripheral atherosclerosis."	3.91	[Clinical study of efficacy and safety of Aducil in patients with chronic lower limb ischaemia]. ( Chupin, AV; Gadzhimuradov, RU; Kalinin, RE; Kamaev, AA; Lar'kov, RN; Parshin, PI; Porsheneva, EV; Suchkov, IA; Uchkin, IG, 2019)
" Conservative treatment included: (a) weight-adjusted bemiparin plus six hours/day intravenous iloprost for 28 days, (b) aspirin (100 mg/day) plus cilostazol (100 mg twice/day) after discharge, and (c) strict recommendations/monitoring for smoking cessation."	3.85	Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia. ( Anastasiadou, C; Galyfos, G; Geropapas, G; Giannakakis, S; Kastrisios, G; Kerasidis, S; Maltezos, C; Papacharalampous, G; Papapetrou, A; Sachmpazidis, I, 2017)
"Cilostazol and L-carnitine have been used as a first-line drug and supplement, respectively, in patients with peripheral arterial disease with intermittent claudication."	3.81	Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats. ( Orito, K; Sahara, H; Shiga, T, 2015)
"The model of IR caused severe muscle injury in the rat hind limb and ischemic preconditioning has a protective effect, reducing myocyte necrosis, however, treatment with cilostazol and also the association between cilostazol and preconditioning has no protective effect on the skeletal muscle subjected to ischemia and reperfusion injury."	3.80	Effects of ischemic preconditioning and cilostazol on muscle ischemia-reperfusion injury in rats. ( Frias Neto, CA; Koike, MK; Montero, EF; Saad, KR; Saad, PF, 2014)
"We tested the hypothesis that clopidogrel and cilostazol combination therapy could effectively attenuate systemic inflammatory reaction, facilitate proliferation of circulating endothelial progenitor cell (EPC), and improve the clinical outcomes of critical limb ischemia (CLI) in patients unsuitable for surgical revascularization or percutaneous transluminal angioplasty (PTA)."	3.80	Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy. ( Chai, HT; Chang, HW; Chen, CH; Chen, YC; Chen, YL; Chua, S; Chung, SY; Ko, SF; Leu, S; Lin, PY; Sheu, JJ; Sung, PH; Tsai, TH; Yip, HK, 2014)
"We studied ischemia-induced neovascularization in the ischemic hindlimb of cilostazol-treated and untreated control mice."	3.79	Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. ( Angelini, F; Arena, V; Biscetti, F; Flex, A; Ghirlanda, G; Locatelli, F; Pecorini, G; Rutella, S; Stigliano, E; Straface, G, 2013)
"Cilostazol is effective for the treatment of peripheral ischemia."	3.79	Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPARγ. ( Angelini, F; Arena, V; Biscetti, F; Ferraccioli, G; Flex, A; Ghirlanda, G; Pecorini, G; Stigliano, E, 2013)
"An experimental study was designed using 30 Wistar rats divided into five groups (n = 6): control (C); ischemia (I) - animals submitted to left common iliac artery interruption without pharmacologic treatment; pentoxifylline (Pen) - rats submitted to procedure and treated with pentoxifylline 3 mg/kg twice a day for 6 weeks; cilostazol (Cil) - animals submitted to procedure and treated with cilostazol 30 mg/kg twice a day for 6 weeks; and sham (S) - animals submitted to procedure without artery interruption."	3.78	Effect of cilostazol and pentoxifylline on gait biomechanics in rats with ischemic left hindlimb. ( Bredarioli, M; Dalio, MB; do Prado, WA; Joviliano, EE; Piccinato, CE, 2012)
"Combined cilostazol-clopidogrel therapy is superior to either agent alone in improving ischemia in rodent CLI."	3.78	Combination of cilostazol and clopidogrel attenuates rat critical limb ischemia. ( Chang, HW; Chen, YL; Chua, S; Leu, S; Lin, KC; Sheu, JJ; Sun, CK; Tsai, CY; Tsai, TH; Yang, JL; Yen, CH; Yip, HK, 2012)
"To investigate the effect of cilostazol, in kidney and skeletal muscle of rats submitted to acute ischemia and reperfusion."	3.78	Effects of cilostazol in kidney and skeletal striated muscle of Wistar rats submitted to acute ischemia and reperfusion of hind limbs. ( Capelozzi, VL; Francisco Neto, A; Moreira Neto, AA; Parra-Cuentas, ER; Rodrigues, OR; Schmidt Júnior, AF; Souza Júnior, SS, 2012)
"Acetylcholine-and A23187-induced relaxation was reduced in the Ischemia/Reperfusion 120/90 group, and treatment with cilostazol partially prevented this ischemia/reperfusion-induced endothelium impairment."	3.78	The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway. ( Capellini, VK; Celotto, AC; Evora, PR; Joviliano, EE; Piccinato, CE; Santos, MR, 2012)
"The present study demonstrates that cilostazol attenuates retinal injury after transient ischemia via inhibition of leukocyte-endothelial cell interactions."	3.74	Neuroprotective effect of cilostazol against retinal ischemic damage via inhibition of leukocyte-endothelial cell interactions. ( Iwama, D; Kiryu, J; Miyahara, S; Miyamoto, K; Tamura, H; Tsujikawa, A; Yamashiro, K; Yoshimura, N, 2007)
" This study investigated whether cilostazol could improve the vasodilatory response of the brachial artery to ischemia, an indicator of endothelial function, in ten male smokers."	3.72	Effect of cilostazol on impaired vasodilatory response of the brachial artery to ischemia in smokers. ( Ebata, K; Kanehara, H; Miyamori, I; Oida, K; Suzuki, J, 2003)
"Cilostazol did not increase the ABI but caused a significant increase in the SPP from 24."	2.76	Cilostazol increases skin perfusion pressure in severely ischemic limbs. ( Iida, O; Miyamoto, A; Miyashita, Y; Nanto, S; Saito, S, 2011)
"Cilostazol treatment also increased freedom from target lesion revascularization (RR, 1."	2.72	Literature review and meta-analysis of the efficacy of cilostazol on limb salvage rates after infrainguinal endovascular and open revascularization. ( Desai, K; Han, B; Kuziez, L; Yan, Y; Zayed, MA, 2021)
"Cilostazol is a new phosphodiesterase inhibitor that suppresses platelet aggregation and also acts as a direct arterial vasodilator."	2.69	Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. ( Cutler, BS; Dawson, DL; Meissner, MH; Strandness, DE, 1998)
"In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb."	2.50	Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014)
"The key areas of treatment focus on smoking cessation, exercise rehabilitation, with supervised therapy if possible, cardiovascular risk prevention with antiplatelet drugs, statins and angiotensin converting enzymes, and correction of atherosclerotic risk factors with well-defined targets (LDL less than 1g/L, HDL greater than 0."	2.45	[Peripheral arterial disease with lower limb claudication: Medical treatment]. ( Bui, HT; Hadj Henni, A; Journet, J; Long, A, 2009)
"Cilostazol is a drug of choice for the treatment of intermittent claudication that also affects innate and adaptive immune cells."	1.56	Cilostazol Mediates Immune Responses and Affects Angiogenesis During the Acute Phase of Hind Limb Ischemia in a Mouse Model. ( Bouziotis, P; Kadoglou, NPE; Kakisis, I; Katsimpoulas, M; Kostomitsopoulos, NG; Kostopoulos, IV; Lazaris, A; Paronis, E; Poulaki, E; Prignon, A; Provost, C; Spyropoulos, C; Stasinopoulou, M; Tsitsilonis, O, 2020)
"Ergotism is an ischaemic complication due to vasoconstriction throughout the body due to ingestion of ergotamine."	1.48	Headache in an HIV-Positive Patient: Dangerous Interaction. ( Garner, O; Iardino, A; Lorusso, G; Lotta, F, 2018)
"Cilostazol is an antiplatelet agent with vasodilatory effects that works by increasing intracellular concentrations of cyclic adenosine monophosphate (cAMP)."	1.43	Cilostazol improves high glucose-induced impaired angiogenesis in human endothelial progenitor cells and vascular endothelial cells as well as enhances vasculoangiogenesis in hyperglycemic mice mediated by the adenosine monophosphate-activated protein kin ( Chao, TH; Chen, JH; Cho, CL; Lee, CH; Li, YH; Liu, PY; Tseng, SY; Wu, HL, 2016)
"Cilostazol has been shown to be beneficial for the improvement of pain-free walking distance in patients with intermittent claudication in a series of randomized clinical trials."	1.43	Induction of Angiogenesis by a Type III Phosphodiesterase Inhibitor, Cilostazol, Through Activation of Peroxisome Proliferator-Activated Receptor-γ and cAMP Pathways in Vascular Cells. ( Carracedo, M; Ikeda-Iwabu, Y; Kanbara, Y; Morishita, R; Muratsu, J; Otsu, R; Rakugi, H; Sanada, F; Sugimoto, K; Taniyama, Y; Yamamoto, K, 2016)
"Cilostazol treatment may be useful for the management of diabetic retinal vascular dysfunction and neuronal degeneration."	1.39	Neuroprotective effects of cilostazol on retinal ganglion cell damage in diabetic rats. ( Jung, KI; Kim, JH; Park, CK; Park, HY, 2013)
"Cilostazol is known to be a selective inhibitor of phosphodiesterase 3 and is generally used to treat intermittent claudication caused by peripheral arterial disease."	1.38	Cilostazol stimulates revascularisation in response to ischaemia via an eNOS-dependent mechanism. ( Hori, A; Komori, K; Morisaki, K; Murohara, T; Shibata, R, 2012)
"Cilostazol is an anti-platelet agent with vasodilatory activity that acts by increasing intracellular concentrations of cAMP."	1.38	A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade. ( Chao, TH; Chen, JH; Cho, CL; Li, YH; Liu, PY; Shi, GY; Tseng, SY; Wu, HL, 2012)
"Outcome measures were binary restenosis by angiogram, reocclusion, target lesion revascularization (TLR), limb salvage rate and complete wound healing at 3 months."	1.38	Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia. ( Hirano, K; Iida, O; Kawasaki, D; Soga, Y; Suzuki, K; Yamaoka, T, 2012)
"Cilostazol is a phosphodiesterase III inhibitor with a firm evidence base for use in intermittent claudication."	1.35	Cilostazol may improve outcome in critical limb ischemia. ( Davies, AH; Franklin, IJ; Shalhoub, J, 2009)

Research

Studies (50)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Number of Participants With New MRI (Magnetic Resonance Image) Lesions on Follow-up MRI

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (2.00)	18.2507
2000's	9 (18.00)	29.6817
2010's	33 (66.00)	24.3611
2020's	7 (14.00)	2.80

Authors	Studies
Sahin, M	1
Baytaroglu, C	1
Sevgili, E	1
Zaki, OS	1
Nassar, NN	1
Abdallah, DM	1
Safar, MM	1
Mohammed, RA	1
Tseng, SY	4
Chang, HY	2
Li, YH	4
Chao, TH	4
Suchkov, IA	1
Kalinin, RE	1
Gadzhimuradov, RU	1
Lar'kov, RN	1
Uchkin, IG	1
Chupin, AV	1
Parshin, PI	1
Kamaev, AA	1
Porsheneva, EV	1
Paronis, E	1
Katsimpoulas, M	1
Kadoglou, NPE	1
Provost, C	1
Stasinopoulou, M	1
Spyropoulos, C	1
Poulaki, E	1
Prignon, A	1
Kakisis, I	1
Kostomitsopoulos, NG	1
Bouziotis, P	1
Kostopoulos, IV	1
Tsitsilonis, O	1
Lazaris, A	1
Desai, K	1
Han, B	1
Kuziez, L	1
Yan, Y	1
Zayed, MA	1
Lee, CY	1
Wu, TC	1
Lin, SJ	1
Shimatani, K	1
Sato, H	1
Saito, A	1
Sasai, M	1
Watanabe, K	1
Mizukami, K	1
Kamohara, M	1
Miyagawa, S	1
Sawa, Y	1
Soga, Y	3
Takahara, M	1
Iida, O	4
Yamauchi, Y	1
Hirano, K	3
Fukunaga, M	1
Zen, K	1
Suzuki, K	3
Shintani, Y	1
Miyashita, Y	3
Tsuchiya, T	2
Yamaoka, T	2
Ando, K	1
Galyfos, G	1
Kerasidis, S	1
Kastrisios, G	1
Giannakakis, S	1
Sachmpazidis, I	1
Anastasiadou, C	1
Geropapas, G	1
Papapetrou, A	1
Papacharalampous, G	1
Maltezos, C	1
Wang, Z	1
Liu, T	1
Chen, X	1
You, H	1
Zhang, Q	1
Xue, J	1
Zheng, Y	1
Luo, D	1
Mii, S	1
Guntani, A	1
Kawakubo, E	1
Tanaka, K	1
Kyuragi, R	2
Iardino, A	1
Garner, O	1
Lorusso, G	1
Lotta, F	1
Coelho da Mota, DS	1
Sicuro, FL	1
Resende, AC	1
De Moura, RS	1
Bottino, DA	1
Bouskela, E	1
Furuyama, T	1
Onohara, T	1
Yamashita, S	1
Yoshiga, R	1
Yoshiya, K	1
Inoue, K	1
Morisaki, K	2
Matsumoto, T	1
Maehara, Y	1
Kan, CD	1
Wang, JN	1
Li, WP	1
Lin, SH	1
Chen, WL	1
Hsu, YP	1
Yeh, CS	1
Jung, KI	1
Kim, JH	1
Park, HY	1
Park, CK	1
Biscetti, F	3
Pecorini, G	2
Arena, V	2
Stigliano, E	2
Angelini, F	2
Ghirlanda, G	2
Ferraccioli, G	2
Flex, A	3
Sheu, JJ	2
Lin, PY	1
Sung, PH	1
Chen, YC	1
Leu, S	2
Chen, YL	2
Tsai, TH	2
Chai, HT	1
Chua, S	2
Chang, HW	2
Chung, SY	1
Chen, CH	1
Ko, SF	1
Yip, HK	2
Spiliopoulos, S	1
Di Minno, G	1
Spadarella, G	1
Cafaro, G	1
Petitto, M	1
Lupoli, R	1
Di Minno, A	1
de Gaetano, G	1
Tremoli, E	1
Azarbal, A	1
Clavijo, L	1
Gaglia, MA	1
Frias Neto, CA	1
Koike, MK	1
Saad, KR	1
Saad, PF	1
Montero, EF	1
Liu, PY	2
Lee, CH	1
Cho, CL	2
Wu, HL	2
Chen, JH	2
Shiga, T	1
Sahara, H	1
Orito, K	1
Sanada, F	1
Kanbara, Y	1
Taniyama, Y	1
Otsu, R	1
Carracedo, M	1
Ikeda-Iwabu, Y	1
Muratsu, J	1
Sugimoto, K	1
Yamamoto, K	1
Rakugi, H	1
Morishita, R	1
Long, A	1
Bui, HT	1
Journet, J	1
Hadj Henni, A	1
Shalhoub, J	1
Davies, AH	1
Franklin, IJ	1
Saito, S	1
Miyamoto, A	1
Nanto, S	1
Hwang, SJ	1
Jeong, YH	1
Kim, IS	1
Park, KS	1
Kang, MK	1
Koh, JS	1
Park, JR	1
Park, Y	1
Koh, EH	1
Kwak, CH	1
Hwang, JY	1
Kim, S	1
Kwon, SU	1
Hong, KS	1
Kang, DW	1
Park, JM	1
Lee, JH	1
Cho, YJ	1
Yu, KH	1
Koo, JS	1
Wong, KS	1
Lee, SH	1
Lee, KB	1
Kim, DE	1
Jeong, SW	1
Bae, HJ	1
Lee, BC	1
Han, MK	1
Rha, JH	1
Kim, HY	1
Mok, VC	1
Lee, YS	1
Kim, GM	1
Suwanwela, NC	1
Yun, SC	1
Nah, HW	1
Kim, JS	1
Hori, A	1
Shibata, R	1
Murohara, T	1
Komori, K	1
Kawasaki, D	2
Nobuyoshi, M	1
Shi, GY	1
Santos, MR	1
Celotto, AC	1
Capellini, VK	1
Evora, PR	1
Piccinato, CE	2
Joviliano, EE	2
Straface, G	1
Rutella, S	1
Locatelli, F	1
Bredarioli, M	1
Dalio, MB	1
do Prado, WA	1
Garimella, PS	1
Hart, PD	1
O'Hare, A	1
DeLoach, S	1
Herzog, CA	1
Hirsch, AT	1
Lin, KC	1
Tsai, CY	1
Yen, CH	1
Sun, CK	1
Yang, JL	1
Moreira Neto, AA	1
Souza Júnior, SS	1
Capelozzi, VL	1
Parra-Cuentas, ER	1
Schmidt Júnior, AF	1
Francisco Neto, A	1
Rodrigues, OR	1
Oida, K	1
Ebata, K	1
Kanehara, H	1
Suzuki, J	1
Miyamori, I	1
Stapanavatr, W	1
Ungkittpaiboon, W	1
Karnjanabatr, B	1
Clagett, GP	1
Sobel, M	1
Jackson, MR	1
Lip, GY	1
Tangelder, M	1
Verhaeghe, R	1
Iwama, D	1
Miyamoto, K	1
Miyahara, S	1
Tamura, H	1
Tsujikawa, A	1
Yamashiro, K	1
Kiryu, J	1
Yoshimura, N	1
Dawson, DL	1
Cutler, BS	1
Meissner, MH	1
Strandness, DE	1
Mohler, ER	1
Beebe, HG	1
Salles-Cuhna, S	1
Zimet, R	1
Zhang, P	1
Heckman, J	1
Forbes, WP	1
Hiatt, WR	1
Nehler, MR	1
Dean, SM	1
Satiani, B	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214]	Phase 4	826 participants (Actual)	Interventional	2016-11-30	Completed
CYP 2C19 Polymorphism and Response to Adjunctive Cilostazol and High Maintenance-dose Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention[NCT01012193]	Phase 4	134 participants (Actual)	Interventional	2008-01-31	Completed
Trial for Efficacy and Safety of Cilostazol on the Progression of Symptomatic Intracranial Stenosis Comparing Clopidogrel[NCT00130039]	Phase 4	457 participants (Actual)	Interventional	2005-08-31	Completed
Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Collateral Formation Assessed by Dual-energy 128-row CT Angiography Mediated Through Multiple Mechanisms in Patients With Mild-to-moderate PAOD[NCT01952756]	Phase 4	44 participants (Actual)	Interventional	2012-01-31	Completed
Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Endothelial Function Mediated Through Modification of Vasculogenesis and Angiogenesis Factors in Patients With Stable Coronary Artery Disease[NCT02174939]	Phase 4	300 participants (Anticipated)	Interventional	2014-02-28	Recruiting
Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells Mediated Through Multiple Mechanisms in Patients With High Risk for Cardiovascular Disease[NCT02194686]	Phase 4	71 participants (Actual)	Interventional	2013-01-31	Completed
Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172]	Phase 4	164 participants (Actual)	Interventional	2008-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

number of patients with new ischemic lesions on FLAIR (Fluid attenuation inversion recovery) images of follow-up MRI, which were determined by slice to slice comparison with baseline MRI. (NCT00130039)
Timeframe: 7 months after treatment

Number of Participants With Overall Cardiovascular Events

Intervention	pariticipants (Number)
Cilostazol	34
Clopidogrel	23

including nonfatal stroke, nonfatal myocardial infarction and vascular death. (NCT00130039)
Timeframe: upto 7 months after randomization

Number of Participants With Progression of Symptomatic Intracranial Stenosis

Intervention	participants (Number)
Cilostazol	15
Clopidogrel	10

"Blind reviewers classified the presence and severity of stenosis on middle cerebral arteries and basilar artery on magnetic resonance angiogram (MRA) into 5 grades; normal, mild, moderate, severe and occlusion. Progression was defined as worsening of stenosis by 1 or more grades on final MRA as compared with the baseline MRA.~The progression of symptomatic stenosis is defined as 1 or more grade worsening of the stenosis on the symptomatic artery on MRA." (NCT00130039)
Timeframe: 7 months after treatment

Number of Participants With Stroke Events

Intervention	participants (Number)
Cilostazol	20
Clopidogrel	32

including nonfatal ischemic stroke, nonfatal hemorrhagic stroke and fatal stroke (NCT00130039)
Timeframe: upto 7 months after randomization

Number of Patients With Ipsilateral Ischemic Stroke Rate

Intervention	participants (Number)
Cilostazol	11
Clopidogrel	7

ischemic stroke event which occured in the vascular territory of initial symptomatic stenosis (NCT00130039)
Timeframe: upto 7 months after randomization

Numbers of Fatal or Major Bleeding Complications

Intervention	participants (Number)
Cilostazol	9
Clopidogrel	5

life-threatening or fatal bleeding was defined as any fatal bleeding event, a drop in hemoglobin of ≥ 50g/L, or significant hypotension with need for inotropic agents, symptomatic intracranial hemorrhage, or transfusion of ≥ 4 units of red-blood cells or equivalent amount of whole blood. Major bleeding was defined as significantly disabling bleedings, intraocular bleeding leading to significant visual loss, or bleeding requiring transfusion of ≤ 3 units of red-blood cells or equivalent amount of whole blood (NCT00130039)
Timeframe: upto 7 months after randomization

Change From Baseline in Claudication Onset Time at Day 180

Intervention	events (Number)
Cilostazol	2
Clopidogrel	6

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

Change From Baseline in Claudication Onset Time at Day 90

Intervention	Log Minutes (Mean)
Cilostazol + L-Carnitine	1.065
Cilostazol + Placebo	0.896

Change From Baseline in Peak Walking Time (PWT) at Day 180

Intervention	Log Minutes (Mean)
Cilostazol + L-Carnitine	1.001
Cilostazol + Placebo	0.815

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

Change From Baseline in Peak Walking Time at Day 180

Intervention	Log Minutes (Mean)
Cilostazol + L-Carnitine	0.241
Cilostazol + Placebo	0.134

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

Change From Baseline in Peak Walking Time at Day 90

Intervention	Log Minutes (Mean)
Cilostazol + L-Carnitine	0.267
Cilostazol + Placebo	0.145

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90

Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 180

Intervention	Log Minutes (Mean)
Cilostazol + L-Carnitine	0.166
Cilostazol + Placebo	0.139

Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180

Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 90

Article	Year
Literature review and meta-analysis of the efficacy of cilostazol on limb salvage rates after infrainguinal endovascular and open revascularization. Journal of vascular surgery, 2021, Volume: 73, Issue:2 Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cilostazol; Critical Illness; Endovascular Procedures	2021
Antiplatelet therapy in critical limb ischemia: update on clopidogrel and cilostazol. The Journal of cardiovascular surgery, 2014, Volume: 55, Issue:5 Topics: Cilostazol; Clopidogrel; Combined Modality Therapy; Critical Illness; Drug Therapy, Combination; End	2014
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. Annals of medicine, 2014, Volume: 46, Issue:7 Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int	2014
Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data? Journal of cardiovascular pharmacology and therapeutics, 2015, Volume: 20, Issue:2 Topics: Aspirin; Cilostazol; Dipyridamole; Endovascular Procedures; Extremities; Humans; Ischemia; Periphera	2015
New therapeutic effects of cilostazol in patients with ischemic disorders. Current vascular pharmacology, 2015, Volume: 13, Issue:3 Topics: Cilostazol; Humans; Ischemia; Tetrazoles; Vasodilator Agents	2015
[Peripheral arterial disease with lower limb claudication: Medical treatment]. Journal des maladies vasculaires, 2009, Volume: 34, Issue:5 Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Cilostazol; Comorbidity; Diabetes Complications; Dr	2009
Peripheral artery disease and CKD: a focus on peripheral artery disease as a critical component of CKD care. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2012, Volume: 60, Issue:4 Topics: Amputation, Surgical; Ankle Brachial Index; Atherosclerosis; Cilostazol; Diabetic Foot; Exercise The	2012
Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Arterial Occlusive Diseases; Aspirin; Cilostazol; Clopidogrel; Contraindications; Evidence-Based Med	2004
Peripheral arterial disease. Advances in internal medicine, 2001, Volume: 47 Topics: Angiotensin-Converting Enzyme Inhibitors; Cilostazol; Diabetes Complications; Diabetes Mellitus; Dis	2001

Article	Year
Effects of Postoperative Percutaneous Coronary Intervention, Pharmacologic Treatment, and Predisposing Factors on Clinical Outcomes in Patients With and Without Type 2 Diabetes Along With Critical Limb Ischemia. Clinical therapeutics, 2021, Volume: 43, Issue:1 Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cilostazol; Diabetes Mellitus, Type 2; Extremities; F	2021
Efficacy of CilostAzol for Below-the-Knee Artery Disease after Balloon AnGioplasty in PatiEnts with Severe Limb Ischemia (CABBAGE Trial). Annals of vascular surgery, 2017, Volume: 45 Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angiography; Angioplasty, Balloon; Cardiovascular Age	2017
Cilostazol increases skin perfusion pressure in severely ischemic limbs. Angiology, 2011, Volume: 62, Issue:1 Topics: Aged; Blood Pressure; Cilostazol; Extremities; Female; Humans; Ischemia; Male; Prospective Studies;	2011
Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. Circulation. Cardiovascular interventions, 2010, Volume: 3, Issue:5 Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Blood Platelet	2010
Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. Stroke, 2011, Volume: 42, Issue:10 Topics: Aged; Aged, 80 and over; Cilostazol; Clopidogrel; Constriction, Pathologic; Disease Progression; Dou	2011
Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation, 1998, Aug-18, Volume: 98, Issue:7 Topics: Adult; Aged; Arteriosclerosis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cilostazol; Double-B	1998
Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication. Vascular medicine (London, England), 2001, Volume: 6, Issue:3 Topics: Aged; Ankle; Blood Pressure; Brachial Artery; Cilostazol; Double-Blind Method; Exercise; Female; Hem	2001

Article	Year
Cardioprotective Effect of Cilostazol on Ischemia-Reperfusion Injury Model. Brazilian journal of cardiovascular surgery, 2022, 12-01, Volume: 37, Issue:6 Topics: Adenosine Triphosphate; Animals; Cilostazol; Disease Models, Animal; Ischemia; Rats; Rats, Wistar; R	2022
Cilostazol Alleviates NLRP3 Inflammasome-Induced Allodynia/Hyperalgesia in Murine Cerebral Cortex Following Transient Ischemia: Focus on TRPA1/Glutamate and Akt/Dopamine/BDNF/Nrf2 Trajectories. Molecular neurobiology, 2022, Volume: 59, Issue:12 Topics: Animals; Brain Ischemia; Brain-Derived Neurotrophic Factor; Carrier Proteins; Cerebral Cortex; Cilos	2022
Effects of Cilostazol on Angiogenesis in Diabetes through Adiponectin/Adiponectin Receptors/Sirtuin1 Signaling Pathway. International journal of molecular sciences, 2022, Nov-27, Volume: 23, Issue:23 Topics: Acetyl-CoA Carboxylase; Adiponectin; AMP-Activated Protein Kinases; Animals; Cilostazol; Diabetes Me	2022
Effects of Cilostazol on Angiogenesis in Diabetes through Adiponectin/Adiponectin Receptors/Sirtuin1 Signaling Pathway. International journal of molecular sciences, 2022, Nov-27, Volume: 23, Issue:23 Topics: Acetyl-CoA Carboxylase; Adiponectin; AMP-Activated Protein Kinases; Animals; Cilostazol; Diabetes Me	2022
Effects of Cilostazol on Angiogenesis in Diabetes through Adiponectin/Adiponectin Receptors/Sirtuin1 Signaling Pathway. International journal of molecular sciences, 2022, Nov-27, Volume: 23, Issue:23 Topics: Acetyl-CoA Carboxylase; Adiponectin; AMP-Activated Protein Kinases; Animals; Cilostazol; Diabetes Me	2022
Effects of Cilostazol on Angiogenesis in Diabetes through Adiponectin/Adiponectin Receptors/Sirtuin1 Signaling Pathway. International journal of molecular sciences, 2022, Nov-27, Volume: 23, Issue:23 Topics: Acetyl-CoA Carboxylase; Adiponectin; AMP-Activated Protein Kinases; Animals; Cilostazol; Diabetes Me	2022
[Clinical study of efficacy and safety of Aducil in patients with chronic lower limb ischaemia]. Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2019, Volume: 25, Issue:3 Topics: Cilostazol; Humans; Intermittent Claudication; Ischemia; Lower Extremity; Platelet Aggregation Inhib	2019
Cilostazol Mediates Immune Responses and Affects Angiogenesis During the Acute Phase of Hind Limb Ischemia in a Mouse Model. Journal of cardiovascular pharmacology and therapeutics, 2020, Volume: 25, Issue:3 Topics: Angiogenesis Inducing Agents; Animals; Cilostazol; Cytokines; Disease Models, Animal; Hindlimb; Immu	2020
A novel model of chronic limb ischemia to therapeutically evaluate the angiogenic effects of drug candidates. American journal of physiology. Heart and circulatory physiology, 2021, 03-01, Volume: 320, Issue:3 Topics: Angiogenesis Inducing Agents; Animals; Blood Flow Velocity; Cells, Cultured; Chronic Disease; Cilost	2021
Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia. VASA. Zeitschrift fur Gefasskrankheiten, 2017, Volume: 46, Issue:6 Topics: Adult; Amputation, Surgical; Ankle Brachial Index; Anticoagulants; Arteritis; Aspirin; Cardiovascula	2017
Low molecular weight fucoidan ameliorates hindlimb ischemic injury in type 2 diabetic rats. Journal of ethnopharmacology, 2018, Jan-10, Volume: 210 Topics: Animals; Cilostazol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relat	2018
Cilostazol Improves Wound Healing in Patients Undergoing Open Bypass for Ischemic Tissue Loss: A Propensity Score Matching Analysis. Annals of vascular surgery, 2018, Volume: 49 Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis Obliterans; Blood Vessel Prosthesis Implantation; C	2018
Headache in an HIV-Positive Patient: Dangerous Interaction. BMJ case reports, 2018, Jun-04, Volume: 2018 Topics: Adult; Anti-HIV Agents; Anticoagulants; Cilostazol; Cytochrome P-450 CYP3A Inhibitors; Dideoxynucleo	2018
Effects of açaí and cilostazol on skin microcirculation and viability of TRAM flaps in hamsters. The Journal of surgical research, 2018, Volume: 228 Topics: Animals; Capillaries; Cilostazol; Cricetinae; Disease Models, Animal; Drug Evaluation, Preclinical;	2018
Prognostic factors of ulcer healing and amputation-free survival in patients with critical limb ischemia. Vascular, 2018, Volume: 26, Issue:6 Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cilostazol; Critical Illness; Debridement; Disease-Fr	2018
Clinical ultrasound stimulating angiogenesis following drug-release from polymersomes on the ischemic zone for peripheral arterial occlusive disease. Nanomedicine : nanotechnology, biology, and medicine, 2018, Volume: 14, Issue:7 Topics: Angiogenesis Inducing Agents; Animals; Arterial Occlusive Diseases; Bronchodilator Agents; Cilostazo	2018
Neuroprotective effects of cilostazol on retinal ganglion cell damage in diabetic rats. The Journal of pharmacology and experimental therapeutics, 2013, Volume: 345, Issue:3 Topics: Animals; Apoptosis; Blood Glucose; Blotting, Western; Body Weight; Cell Death; Cilostazol; Diabetic	2013
Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPARγ. Molecular and cellular endocrinology, 2013, Dec-05, Volume: 381, Issue:1-2 Topics: Angiogenesis Inducing Agents; Animals; Cilostazol; Diabetes Mellitus, Experimental; Hindlimb; Ischem	2013
Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy. Journal of translational medicine, 2014, Apr-17, Volume: 12 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Base Sequence; Cilostazol; Clopidogrel; DNA Pr	2014
Effects of ischemic preconditioning and cilostazol on muscle ischemia-reperfusion injury in rats. Acta cirurgica brasileira, 2014, Volume: 29 Suppl 3 Topics: Animals; Cilostazol; Hindlimb; Ischemia; Ischemic Preconditioning; Male; Models, Animal; Muscle Fibe	2014
Cilostazol improves high glucose-induced impaired angiogenesis in human endothelial progenitor cells and vascular endothelial cells as well as enhances vasculoangiogenesis in hyperglycemic mice mediated by the adenosine monophosphate-activated protein kin Journal of vascular surgery, 2016, Volume: 63, Issue:4 Topics: AMP-Activated Protein Kinases; Angiogenesis Inducing Agents; Animals; Cell Adhesion; Cell Movement;	2016
Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats. Pharmacology, 2015, Volume: 96, Issue:5-6 Topics: Angiogenic Proteins; Animals; Carnitine; Cilostazol; Disease Models, Animal; Drug Therapy, Combinati	2015
Induction of Angiogenesis by a Type III Phosphodiesterase Inhibitor, Cilostazol, Through Activation of Peroxisome Proliferator-Activated Receptor-γ and cAMP Pathways in Vascular Cells. Arteriosclerosis, thrombosis, and vascular biology, 2016, Volume: 36, Issue:3 Topics: Angiogenesis Inducing Agents; Angiopoietin-1; Animals; Capillaries; Cells, Cultured; Cilostazol; Cyc	2016
Cilostazol may improve outcome in critical limb ischemia. International angiology : a journal of the International Union of Angiology, 2009, Volume: 28, Issue:5 Topics: Administration, Oral; Aged; Aged, 80 and over; Amputation, Surgical; Cilostazol; Critical Illness; F	2009
Cilostazol stimulates revascularisation in response to ischaemia via an eNOS-dependent mechanism. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2012, Volume: 43, Issue:1 Topics: Angiogenesis Inducing Agents; Animals; Blotting, Western; Capillaries; Cilostazol; Disease Models, A	2012
Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia. Journal of vascular surgery, 2011, Volume: 54, Issue:6 Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Arterial Occlusive Diseases; Cilostazol; Female; Femo	2011
A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade. Clinical science (London, England : 1979), 2012, Aug-01, Volume: 123, Issue:3 Topics: Animals; Antigens, CD34; Apoptosis; Blood Vessels; Cell Movement; Cell Proliferation; Cilostazol; Co	2012
A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade. Clinical science (London, England : 1979), 2012, Aug-01, Volume: 123, Issue:3 Topics: Animals; Antigens, CD34; Apoptosis; Blood Vessels; Cell Movement; Cell Proliferation; Cilostazol; Co	2012
A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade. Clinical science (London, England : 1979), 2012, Aug-01, Volume: 123, Issue:3 Topics: Animals; Antigens, CD34; Apoptosis; Blood Vessels; Cell Movement; Cell Proliferation; Cilostazol; Co	2012
A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade. Clinical science (London, England : 1979), 2012, Aug-01, Volume: 123, Issue:3 Topics: Animals; Antigens, CD34; Apoptosis; Blood Vessels; Cell Movement; Cell Proliferation; Cilostazol; Co	2012
A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade. Clinical science (London, England : 1979), 2012, Aug-01, Volume: 123, Issue:3 Topics: Animals; Antigens, CD34; Apoptosis; Blood Vessels; Cell Movement; Cell Proliferation; Cilostazol; Co	2012
A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade. Clinical science (London, England : 1979), 2012, Aug-01, Volume: 123, Issue:3 Topics: Animals; Antigens, CD34; Apoptosis; Blood Vessels; Cell Movement; Cell Proliferation; Cilostazol; Co	2012
A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade. Clinical science (London, England : 1979), 2012, Aug-01, Volume: 123, Issue:3 Topics: Animals; Antigens, CD34; Apoptosis; Blood Vessels; Cell Movement; Cell Proliferation; Cilostazol; Co	2012
A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade. Clinical science (London, England : 1979), 2012, Aug-01, Volume: 123, Issue:3 Topics: Animals; Antigens, CD34; Apoptosis; Blood Vessels; Cell Movement; Cell Proliferation; Cilostazol; Co	2012
A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade. Clinical science (London, England : 1979), 2012, Aug-01, Volume: 123, Issue:3 Topics: Animals; Antigens, CD34; Apoptosis; Blood Vessels; Cell Movement; Cell Proliferation; Cilostazol; Co	2012
The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway. Clinics (Sao Paulo, Brazil), 2012, Volume: 67, Issue:2 Topics: Animals; Cilostazol; Disease Models, Animal; Femoral Artery; Hindlimb; Ischemia; Male; Nitric Oxide;	2012
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3 Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo	2013
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3 Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo	2013
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3 Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo	2013
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3 Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo	2013
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3 Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo	2013
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3 Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo	2013
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3 Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo	2013
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3 Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo	2013
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3 Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo	2013
Effect of cilostazol and pentoxifylline on gait biomechanics in rats with ischemic left hindlimb. Journal of vascular surgery, 2012, Volume: 56, Issue:2 Topics: Animals; Biomechanical Phenomena; Cilostazol; Gait; Hindlimb; Ischemia; Male; Pentoxifylline; Rats;	2012
Combination of cilostazol and clopidogrel attenuates rat critical limb ischemia. Journal of translational medicine, 2012, Aug-16, Volume: 10 Topics: Animals; Blotting, Western; Cilostazol; Clopidogrel; Drug Therapy, Combination; Extremities; Flow Cy	2012
Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2012, Volume: 44, Issue:6 Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Chi-Square Distribution; Cilos	2012
Effects of cilostazol in kidney and skeletal striated muscle of Wistar rats submitted to acute ischemia and reperfusion of hind limbs. Acta cirurgica brasileira, 2012, Volume: 27, Issue:11 Topics: Animals; Apoptosis; Caspase 3; Cilostazol; Disease Models, Animal; Hindlimb; In Situ Nick-End Labeli	2012
Effect of cilostazol on impaired vasodilatory response of the brachial artery to ischemia in smokers. Journal of atherosclerosis and thrombosis, 2003, Volume: 10, Issue:2 Topics: Adult; Arm; Brachial Artery; Cilostazol; Endothelium, Vascular; Humans; Hyperemia; Ischemia; Male; M	2003
Conservative regimen for chronic critical limb ischemia. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2004, Volume: 87, Issue:3 Topics: Chi-Square Distribution; Cilostazol; Diet, Vegetarian; Exercise Therapy; Female; Humans; Ischemia; L	2004
Neuroprotective effect of cilostazol against retinal ischemic damage via inhibition of leukocyte-endothelial cell interactions. Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:4 Topics: Animals; Blood Platelets; Cell Communication; Cilostazol; Endothelium, Vascular; Fibrinolytic Agents	2007
Three cases of digital ischemia successfully treated with cilostazol. Vascular medicine (London, England), 2001, Volume: 6, Issue:4 Topics: Adult; Cilostazol; Fingers; Humans; Ischemia; Male; Middle Aged; Tetrazoles; Treatment Outcome; Vaso	2001

cilostazol and Ischemia